Last reviewed · How we verify
Shan5
At a glance
| Generic name | Shan5 |
|---|---|
| Sponsor | Shantha Biotechnics Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine (PHASE4)
- Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine (PHASE4)
- Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shan5 CI brief — competitive landscape report
- Shan5 updates RSS · CI watch RSS
- Shantha Biotechnics Limited portfolio CI